Amylyx Pharmaceuticals, Inc. AMLX 深 沪
已收盘 09-05 16:00:00 美东时间
10.20
+0.250
+2.51%
华盛通- 最 高10.2383
- 今 开10.05
- 成交量 175.23万股
- 最 低 9.75
- 昨 收 9.95
- 总市值 9.09亿
- 52周最高 10.2383
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.59
- 委 比 -76.02%
- 总股本 8914.11万
- 历史最高 41.9297
- 量 比 1.06
- 振 幅 4.91%
- 历史最低 1.575
- 每 手 1
- 风险率 1.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amylyx Pharma To Discontinue ORION Program Of AMX0035 In Adults Living With Progressive Supranuclear Palsy
- AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24- AMX0035 continued to be generally well-toleratedAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company")
08-27 19:15
Which under-the-radar winners have the best chance for further gains?
Looking for smaller stocks that have attracted strong investor interest so far in 2025, but are still positioned for further gains? The list below is meant to focus on those names. It contains stocks ...
08-07 22:15
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia.
07-15 02:15
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Goldman Sachs Reinstates Buy on Amylyx Pharmaceuticals, Announces $10 Price Target
Goldman Sachs analyst Corinne Johnson reinstates Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and announces $10 price target.
07-11 02:12
Amylyx to Spotlight Breakthrough Hypoglycemia Drug Avexitide at ENDO 2025 Investor Event
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it will host an investor event at the Endocrine Society's annual meeting (ENDO 2025) on Sunday, July 13, 2025, at 6:00 p.m. PT,
07-08 19:03
美股牛股 | 纳比特大涨超36%，公司宣布为币安币储备大额可转换票据；内克塔治疗飙升逾150%
纳比特大涨超36%，公司宣布为币安币储备大额可转换票据；内克塔治疗飙升逾150%，皮炎药物临床试验结果良好；安霸拟考虑出售公司，隔夜涨超20%>>
06-25 19:15
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
